Cationic lipid
US-2015343062-A1 · Dec 3, 2015 · US
(3,4-dichloro-phenyl)-((S)-3-propyl-pyrrolidin-3-yl)-methanone hydrochloride and manufacturing processes
US9527810B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9527810-B2 |
| Application number | US-201414522775-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 24, 2014 |
| Priority date | Apr 25, 2012 |
| Publication date | Dec 27, 2016 |
| Grant date | Dec 27, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is concerned with a novel process for the preparation of a compound of formula I and its hydrates The compounds of formula I and the corresponding hydrates are pharmaceutically active substances.
First claim
Opening claim text (preview).
The invention claimed is: 1. A crystalline polymorph of (3,4-Dichloro-phenyl)-((S)-3-propyl-pyrrolidin-3-yl)-methanone hydrochloride of formula I or a hydrate thereof. 2. The crystalline polymorph of claim 1 which is (3,4-Dichloro-phenyl)-((S)-3-propyl-pyrrolidin-3-yl)-methanone hydrochloride quarterhydrate. 3. The crystalline polymorph of the compound of claim 1 , wherein the crystalline polymorph has an X-ray powder diffraction pattern having at least one characteristic peak expressed in values of degrees 2-theta at approximately degree 2-theta 5.5 9.4 10.6 12.5 14.6 16.2 16.6 17.3 18.6 19.6 22.2 22.7 23.1 23.7 25.3. 4. The crystalline polymorph of the compound of claim 1 , wherein the crystalline polymorph has an X-ray powder diffraction pattern having characteristic peaks expressed in values of degrees 2-theta at approximately degree 2-theta 5.5 9.4 10.6 12.5 14.6 16.2 16.6 17.3 18.6 19.6 22.2 22.7 23.1 23.7 25.3. 5. The crystalline polymorph of the compound of claim 1 , wherein the crystalline polymorph has an X-ray powder diffraction pattern as shown in FIG. 1 . 6. Substantially pure crystalline polymorph of 3,4-Dichloro-phenyl)-((S)-3-propyl-pyrrolidin-3-yl)-methanone hydrochloride quarterhydrate according to claim 1 . 7. The crystalline polymorph of the compound of claim 1 , wherein the crystalline polymorph has the following unit cell parameters a 6.14 Å b 16.70 Å c 17.43 Å alpha 66.73° beta 81.47° gamma 86.51°. 8. The crystalline polymorph of the compound of claim 1 , wherein the crystalline polymorph has an X-ray powder diffraction pattern having at least one characteristic peak expressed in values of degrees 2-theta at approximately degree 2-theta 5.2 10.5 12.3 15.3 15.6 16.0 17.1 18.8 23.0 23.9 27.2 28.2 30.5. 9. The crystalline polymorph of the compound of claim 1 , wherein the crystalline polymorph has an X-ray powder diffraction pattern as shown in FIG. 2 . 10. A pharmaceutical composition comprising a crystalline polymorph of a compound of claim 1 and a pharmaceutically acceptable carrier. 11. A method for treating depression, anxiety, or both, said method comprising administering to a subject in need thereof an effective amount of a crystalline polymorph of a compound of claim 1 .
Assignees
Inventors
Classifications
Antidepressants · CPC title
- C07D207/08Primary
with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms · CPC title
Anxiolytics · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9527810B2 cover?
- The present invention is concerned with a novel process for the preparation of a compound of formula I and its hydrates The compounds of formula I and the corresponding hydrates are pharmaceutically active substances.
- Who is the assignee on this patent?
- Hoffmann La Roche
- What technology area does this patent fall under?
- Primary CPC classification C07D207/08. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).